Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Q2 2019 Earnings Conference Call August 5, 2019 8:30 AM ET
Company Participants
Allen Baharaff - President and Chief Executive Officer
Yohai Stenzler - Chief Financial Officer
Tali Gorfine - Chief Medical Officer
Liat Hayardeny - Chief Scientific Officer
Conference Call Participants
Yasmeen Rahimi - Roth Capital Partners
Adam Walsh - Stifel
Steve Seedhouse - Raymond James
Ed Arce - H.C. Wainwright
Mayank Mamtani - B. Riley FBR
Operator
Good day, and welcome to the Galmed Conference Call to discuss Financial Results for Second Quarter of 2019. Today's conference is being recorded. Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements, forecasts regarding anticipated timelines, and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to future events.
These statements are based on beliefs and expectations of management as of today and actual results, trends, timelines, projections relating to our financial position and projected development programs and pipeline could differ materially.
We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including limitation the risk under the heading Risk Factors described in our Annual Report on Form 20-F filed with the SEC, and the risks and uncertainties included in the Form 6-K filed with the SEC earlier today. Galmed assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates only.
I would now like to turn the call over to Allen Baharaff, President and Chief Executive Officer. Allen, please go ahead.
Allen Baharaff
Thank you, Sherry. Good morning and thank you for joining us on today's conference call. I'm pleased to be here today with our Chief Scientific Officer, Dr. Liat Hayardeny; our Chief Medical Officer, Dr. Tali
- Read more current GLMD analysis and news
- View all earnings call transcripts